CLOs on the Move

IO Biotech

www.iobiotech.com

 
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.iobiotech.com
  • 430 East 29th Street Suite 940
    New York, NY USA 10016
  • Phone: 646.440.9310

Executives

Name Title Contact Details
Devin Smith
General Counsel and Chief Compliance Officer Profile

Similar Companies

Crinetics

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company`s lead product candidate, paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase 3 program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as CRN04894, an investigational, oral, nonpeptide ACTH antagonist for the treatment of Cushing`s disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company`s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company.

IQuum

IQuum is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nohla Therapeutics

Nohla Therapeutics is a cellular therapy company driven to provide leading off the shelf therapies for patients with critical diseases. Nohla’s first product is a universal donor cell therapy targeting hematopoietic recovery and chemotherapy induced neutropenia, and is being extended to treat a range of other medical indications. This and other products in the pipeline are based on a unique umbilical cord blood expansion platform developed at the Fred Hutchinson Cancer Research Center

Kamiya Biomedical Company

Kamiya Biomedical Company is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Agrivida

Agrivida is developing and commercializing solutions that are the next evolutionary step in animal nutrition, using the plant as a factory to produce and deliver highly differentiated products. We are transforming the economics of enzyme and animal feed production through our use of plant-expressed enzymes and plant modification to develop transformational products for monogastric and ruminant animal nutrition.